Clinical Trials Logo

Epilepsy, Drug Resistant clinical trials

View clinical trials related to Epilepsy, Drug Resistant.

Filter by:
  • None
  • Page 1

NCT ID: NCT06436547 Not yet recruiting - Clinical trials for Epilepsy, Drug Resistant

Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Subiculum as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis

NCT ID: NCT06364085 Not yet recruiting - Clinical trials for Epilepsy, Drug Resistant

Enhancing Epilepsy Management With Precision Deep Brain Stimulation

EPI-BOOST
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.

NCT ID: NCT06248333 Recruiting - Clinical trials for Epilepsy, Drug Resistant

Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy

STEM
Start date: February 14, 2024
Phase: N/A
Study type: Interventional

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor epilepsy.

NCT ID: NCT04673071 Recruiting - Acupuncture Therapy Clinical Trials

Effectiveness and Safety of Thread Embedding Acupuncture for Drug Resistant Epilepsy

Start date: November 17, 2020
Phase: N/A
Study type: Interventional

Epilepsy is one of the most common neurological diseases all over the world. Currently, about 70 million people have epilepsy worldwide. In particular, more than 30% of epilepsy patients still have seizures even though they are treated with appropriate anti-epileptic drugs (AEDs). This number has remained unchanged even after more than 20 years with many new anti-epileptic drugs being introduced. According to International League Against Epilepsy (ILAE), drug-resistant epilepsy is defined when a patient does not achieve seizure-free the seizure with two optimal antiepileptic drugs. This clinical trial is designed to evaluate the effectiveness and safety of thread-embedding acupuncture (TEA) as palliative treatment of drug resistant epilepsy.

NCT ID: NCT04181229 Completed - Clinical trials for Epilepsy, Drug Resistant

Deep Brain Stimulation Post Failed Vagal Nerve Stimulation

DBSpostVNS
Start date: November 25, 2019
Phase: N/A
Study type: Interventional

This is a multicenter, non-blinded, patient preference comparative trial for efficacy of deep brain stimulation (DBS) on drug-resistant epilepsy compared to continued vagal nerve stimulation (VNS) optimization in children with failed VNS. The two conditions being compared are therefore DBS (treatment) versus VNS (control). Fifty (50) patients will be recruited and enrolled in this pilot study (25 from The Hospital for Sick Children and 50 from CHU Sainte-Justine).

NCT ID: NCT04166305 Recruiting - Clinical trials for Epilepsy, Drug Resistant

Drug Resistant Epilepsy: Clinical and Genetic Study

Start date: November 1, 2019
Phase:
Study type: Observational

This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.

NCT ID: NCT03860298 Completed - Clinical trials for Drug Resistant Epilepsy

Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy

Start date: June 17, 2019
Phase: N/A
Study type: Interventional

This study is to evaluate the safety and the intracranial electroencephalography (iEEG) changes of using NaviFUS System for the treatment of patients with drug resistant epilepsy.

NCT ID: NCT03183076 Completed - Clinical trials for Epilepsy, Drug Resistant

Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy

Start date: September 1, 2015
Phase: N/A
Study type: Interventional

The Atkins Diet Modified (ADM) is the best alternative treatment for drug-resistant epilepsy, There is a high prevalence worldwide , especially in Latin American countries, including Mexico. Low income earners, many of which do not have a social security, must meet the high costs by Antiepileptic Drugs (AEDS), which in addition should be used in conjunction or combination therapy, because monotherapy is insufficient . The diet adkins makes some changes in the traditional food habits by others that are accessible and not necessarily expensive, whose mechanism allows for better control of the seizures.